Related Experiment Video

Updated: Jul 4, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.6K

Glp-1 Mimetics and Autophagy in Diabetic Milieu: State-of-the-Art

Habib Yaribeygi1, Mina Maleki2, Raul D Santos3

  • 1Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.

Current Diabetes Reviews
|February 1, 2024
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) mimetics may offer benefits beyond glucose control by modulating autophagy. This review explores how GLP-1 mimetics impact autophagy and potential therapeutic pathways for diabetic complications.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Endocrinology

Background:

  • Diabetes mellitus triggers pathophysiological pathways leading to tissue injury and complications.
  • Autophagy, a cellular degradation process, is crucial for survival but can become pathological in diabetes.
  • Autophagy modulation presents a potential therapeutic target for diabetic complications.

Purpose of the Study:

  • To review the impact of Glucagon-like peptide-1 (GLP-1) mimetics on autophagy.
  • To explore the potential extra-glycemic benefits of GLP-1 mimetics through autophagy modulation.
  • To elucidate the underlying molecular pathways involved in GLP-1 mimetic-mediated autophagy.

Main Methods:

  • Literature review of existing studies on GLP-1 mimetics and autophagy.
  • Analysis of preclinical and clinical data regarding the effects of GLP-1 on cellular processes.
  • Synthesis of current knowledge on the molecular mechanisms linking GLP-1 signaling to autophagy pathways.

Main Results:

  • GLP-1 mimetics show potential in modulating autophagy, influencing cellular homeostasis.
  • Evidence suggests GLP-1 mimetics may confer tissue-protective effects independent of glucose lowering.
  • Specific molecular pathways mediating the interaction between GLP-1 and autophagy require further investigation.

Conclusions:

  • GLP-1 mimetics may offer significant therapeutic advantages by targeting autophagy in diabetic patients.
  • Understanding the interplay between GLP-1 and autophagy could unlock novel treatment strategies for diabetic complications.
  • Further research is warranted to fully elucidate the mechanisms and clinical utility of GLP-1 mimetics in modulating autophagy.
Keywords:
Diabetes mellitusGlp-1 mimeticGlucagon-like peptide-1autophagymolecular pathways.sitagliptin

More Related Videos

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

65.3K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.3K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
323
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
175
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.3K